Policies that would require manufacturers to support legacy technologies indefinitely would therefore likely have significant impacts on their ability to provide new and innovative technologies, as their resources would necessarily have to be spent maintaining their legacy products. This would likely lead to a decrease in the invention and development of new, advanced treatments and procedures that might otherwise help meet the health care sector’s primary motivation: the health and well-being of patients.

Collecting these issues under the heading “Supported Lifetimes,” the Committee today requests information regarding legacy technology challenges, opportunities, considerations, and suggestions in the health care sector. Please be advised that submissions sent to supportedlifetimes@mail.house.gov will be made publicly available to help further the discussion around how best to approach supported lifetimes and legacy technologies.

Click Here to Read the MITA Comment Letter